Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
34 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
OPHTALMOLOGIE SAINT LAZARE
92 RUE SAINT LAZARE, 75009 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
International journal of biological macromolecules · 2025
Developmental medicine and child neurology · 2025
AbstractAimTo quantify optic nerve hypoplasia (ONH) and septo‐optic‐pituitary dysplasia (SOD) morbidities and comorbidities.MethodA retrospective population‐based study with a case–control design was undertaken using administrative health data from Manitoba, Canada. Cases were 124 patients with ONH or SOD (70 males, 54 females; age range 6 months–36 years 8 months [mean 13 years, SD 7 years 2 months]) diagnosed from 1990 to 2019, matched to 620 unrelated population‐based controls (350 males, 270 females; age range 0–36 years 8 months [mean 12 years 5 months, SD 7 years 2 months]) on birth year, sex, and area of residence. Additionally, 76 cases with ONH or SOD (46 males, 30 females; age range 2 years 5 months–36 years 8 months [mean 13 years 11 months, SD 7 years 3 months]) were matched one‐to‐one with sibling controls (40 males, 36 females; age range 7 months–33 years 1 month [mean 11 years 8 months, SD 7 years 3 months]). We used χ2 or Fisher's exact tests to test for differences in prevalence in morbidities and comorbidities between cases and controls; odds ratios (ORs) with 95% confidence intervals (CIs) were estimated. Cox proportional hazards models were used to test for differences in subgroups of cases; hazard ratios and 95% CIs were estimated.ResultsVisual impairment and visual impairment with hypopituitarism were core morbidities associated with ONH and SOD cases respectively compared to unrelated controls (OR = 58.6, 95% CI = 22.5–152.5; OR = 243.4, 95% CI = 32.9–1799.0 respectively). Developmental delay or intellectual disability (OR = 6.9, 95% CI = 3.3–14.4), autism spectrum disorder (OR = 4.0, 95% CI = 2.0–8.3), epilepsy (OR = 14.9, 95% CI = 6.1–36.5), cerebral palsy (OR = 40.9, 95% CI = 14.0–119.6), and mood or anxiety disorders (OR = 1.7, 95% CI = 1.0–2.8) were the comorbidities more common among cases with ONH and SOD. Cases matched to siblings showed similar results except for mood and anxiety disorders.InterpretationVisual impairment and visual impairment with hypopituitarism are the main morbidities in patients with ONH and SOD respectively, while developmental delay or intellectual disability, autism spectrum disorder, epilepsy, cerebral palsy, and mood or anxiety disorders are important comorbidities.
Annals of surgical oncology · 2025
Abstract Background Preoperative delay when treating breast cancer confers poorer outcomes, but growth rates and the upstaging likelihoods per delay interval remain unknown. This study evaluated upstaging risk, nodal spread, and tumor growth rates in vivo while awaiting treatment. Patients and Methods Registry-based data from the national cancer database was reviewed for patients treated between 2010 and 2020 at commission on cancer-accredited facilities, with nonmetastatic, noninflammatory breast cancer, undergoing surgery first. Results Among 1,018,219 patients, 11.5% had primary tumoral upstaging and 14.1% had nodal upstaging. For every 30 d between diagnosis and surgery, the adjusted odds ratios (ORs) for tumor upstaging was 1.11 for ductal carcinoma in situ (DCIS) (95% CI 1.09–1.13, P < 0.0001), 1.13 for cT1 (95% CI 1.11–1.15, P < 0.0001), and 1.18 for cT2 tumors (95% CI 1.15–1.21, P < 0.0001). For invasive tumors, the adjusted 30-d ORs for upstaging in triple negative (TN) primaries were higher (P < 0.0001) at 1.21 (95% CI 1.17–1.25) than hormone receptor-positive (HR+, 1.13; 95% CI 1.12–1.15) and human epidermal growth factor 2-positive (HER2+, 1.09; 95% CI 1.04–1.13). cN0 patients had an adjusted OR for upstaging to node-positive of 1.07 (95% CI 1.06–1.08, P < 0.0001). The number of 30-d intervals for cT1a, cT1b, cT1c, and cT2 tumors to grow 1 mm was 3.95, 2.63, 2.27, and 1.92, respectively, with tumor growth faster in TN tumors (1.29) than HER2+ (4.95) or HR+ (2.35) (P < 0.0001). Conclusions Longer delays risk greater upstaging and nodal spread, explaining the association with higher disease-specific and overall mortality in prior studies. Larger and TN tumors have larger delay-associated upstaging likelihoods and in vivo growth rates, making preoperative delays more impactful in these groups.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Nature genetics · 2026 · Journal Article
Moolhuijsen LME, Zhu J, Mullin BH, Pujol-Gualdo N, et al.
NPJ breast cancer · 2026 · Journal Article
Mokbel K, Weedon MN, Moye V, Ruth KS, et al.
Journal of public health management and practice : JPHMP · 2026 · Journal Article
Alongi J, Lankau EW, Dudley J, Sneed J, et al.
Journal of clinical tuberculosis and other mycobacterial diseases · 2025 · Case Reports
Albert O, Lazarus O, Benjamin OJ, Ben O, et al.
Social science & medicine (1982) · 2025 · Introductory Journal Article
Brewis A, SturtzSreetharan C, Ruth A
Cureus · 2025 · Journal Article
Raoof A, Rathod J, Banothu G, Kummari S, et al.
NEJM AI · 2025 · Journal Article
Ruth PS, Uhlrich SD, de Monts C, Falisse A, et al.
Plant disease · 2025 · Journal Article
Hernandez AP, Bloomingdale C, Ruth S, Cushnie E, et al.
bioRxiv : the preprint server for biology · 2025 · Journal Article
Ruth PS, Uhlrich SD, de Monts C, Falisse A, et al.
Annals of surgical oncology · 2025 · Journal Article
Bleicher RJ, Ruth KJ, Williams AD, Ross EA, et al.
The Journal of steroid biochemistry and molecular biology · 2025 · Journal Article
Sanaye M, Alva M, Wani T, Banerjee A, et al.
Developmental medicine and child neurology · 2025 · Journal Article
Salman MS, Ruth CA, Yogendran MS, Lix LM
International journal of biological macromolecules · 2025 · Journal Article
Rajesh A, Sajeev D, R NK, Rangasamy J, et al.
ASAIO journal (American Society for Artificial Internal Organs : 1992) · 2026 · Journal Article
Ruth A, Kennedy C
Clinical nutrition (Edinburgh, Scotland) · 2026 · Journal Article
Mehta S, Huey SL, Ghugre PS, Potdar RD, et al.
Pediatric neurology · 2026 · Journal Article
Salman MS, Ruth CA, Walld R, Yogendran MS, et al.
Southern medical journal · 2026 · Journal Article
Cureus · 2026 · Journal Article
R GS, K N
Pediatric dermatology · 2025 · Journal Article
Lopes FCPS, Levy ML, Ruth JS, Priola G, et al.
Health economics review · 2025 · Journal Article
Shobha V, Singhai S, Haridas V, V S, et al.
Clinical nutrition ESPEN · 2025 · Journal Article
J N H, G G, Mahadevan S, R I
American journal of veterinary research · 2026 · Journal Article
Baumruck R, Tagudar J, Doyle P, Durgempudi P, et al.
International journal of environmental research and public health · 2026 · Journal Article
Kowalski V, Hajek A, Van Rüth V, Graf W, et al.
Paediatrics & child health · 2025 · Journal Article
Abulannaz O, Ruth C, Dragan R, Dufault B, et al.
Scientific reports · 2025 · Journal Article
Heinrich F, Wong TLE, Graf W, Dost K, et al.
Clinical nutrition (Edinburgh, Scotland) · 2026 · Journal Article
Mehta S, Huey SL, Ghugre PS, Potdar RD, et al.
NPJ breast cancer · 2026 · Journal Article
Reimer T, Stachs A, Veselinovic K, Kuehn T, et al.
Clinical nutrition ESPEN · 2025 · Journal Article
J N H, G G, Mahadevan S, R I
International journal of environmental research and public health · 2026 · Journal Article
Kowalski V, Hajek A, Van Rüth V, Graf W, et al.
Cureus · 2025 · Case Reports
K R, J P, R R, B V MM, et al.
Cureus · 2026 · Case Reports
R S, Nanda M S, Adalarasan S, Subramanian Y, et al.
Journal of cancer research and clinical oncology · 2026 · Journal Article
Gambichler T, Brune J, Rüth J, Abu Rached N, et al.
Hays KL, Ruth NM, Nietert PJ, Muhammad LN, et al.
Pediatric dermatology · 2025 · Journal Article
Lopes FCPS, Levy ML, Ruth JS, Priola G, et al.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2025 · Journal Article
Salman MS, Ruth CA, Yogendran M, Lix L
Pediatric cardiology · 2025 · Journal Article
Elsisy MF, Ruth T, Coyan G, Dulek DE, et al.
Journal of paediatrics and child health · 2025 · Journal Article
Salman MS, Ruth CA, Yogendran MS, Lix LM
Arthritis care & research · 2025 · Journal Article
Ruth NM
Perfusion · 2025 · Journal Article
Doane K, Guffey D, Loftis LL, Nguyen TC, et al.
Arthritis care & research · 2025 · Journal Article
Ruth NM